ClinicalTrials.gg
RecruitingNCT06203210IDeate-Lung02Updated Aug 6, 2026

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

A Phase 3 interventional study of Ifinatamab deruxtecan and Topotecan in Small Cell Lung Cancer, sponsored by Daiichi Sankyo. Recruiting at 229 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 629 studies in Small Cell Lung Carcinoma with a site in United States — 111 open to participants now, 182 under way, 26 of them phase 3. Small Cell Lung Carcinoma · United States.

Planned enrollment
35th of 550
540 · median 55
Started
2024
with 17 others
Phase 3
50 of 629
11 open now
Primary completion
2028-01
later than 100 of 181 live
Registered
544th of 629
by date

Among the 629 studies in Small Cell Lung Carcinoma with a site in United States, this one is the 35th largest by planned enrollment of the 550 interventional ones that give a count, is one of 18 that started in 2024, is one of 50 in phase 3, reaches primary completion later than 100 of the 181 other live ones, and was the 544th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

111 of the 629 studies in Small Cell Lung Carcinoma with a site in United States are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 629 studies in Small Cell Lung Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).

Read the detailed description

The primary objective of this study is to assess whether treatment with I-DXd prolongs overall survival (OS) compared with treatment of physician's choice among participants with relapsed SCLC.

The secondary objectives of the study are to further evaluate the efficacy/safety of I-DXd, health economics and outcome research measures (including patient reported outcomes), immunogenicity of I-DXd, B7-H3 protein expression, and characterize the pharmacokinetics of I-DXd.

03

Conditions studied

  • Small Cell Lung Cancer

Keywords

  • Small cell lung cancer
  • Ifinatamab deruxtecan
  • I-DXd
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all the following criteria to be eligible for randomization into the study:

  1. Sign and date the form (ICF) prior to the start of any study-specific qualification procedures.
  2. Adults greater than or equal to (≥)18 years or the minimum legal adult age (whichever is greater) at the time the ICF is signed.
  3. Has or cytologically documented extensive-stage small cell lung cancer (ES-SCLC).
  4. The participant must provide adequate baseline tumor samples with sufficient quantity and quality of tumor tissue content.
  5. Has received prior therapy with only one prior platinum-based line as systemic therapy for SCLC with at least 2 cycles of therapy and a chemotherapy free-interval [CTFI] (duration from stop date of the platinum agent in 1L therapy to radiological PD) of ≥30 days.
  6. Has at least 1 according to v1.1 as assessed by the investigator.
  7. Has documentation of radiological disease progression on or after the most recent systemic therapy.
  8. Has PS of less than or equal to (≤)1 within 7 days prior to Cycle 1 Day 1 (C1D1).
  9. Participants with / are eligible if protocol specified criteria are met.

Exclusion criteria

Exclusion Criteria

Participants who meet any of the following criteria will be disqualified from entering the study:

  1. Has received prior treatment with orlotamab, enoblituzumab, or other B7 homologue 3 (B7-H3) targeted agents, including I-DXd.
  2. Prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities.
  3. Has received any of the comparators used in this study or any topoisomerase I inhibitor.
  4. Has inadequate before randomization as specified in the protocol.
  5. Has any of the following conditions within the past 6 months: cerebrovascular accident, , or another arterial thromboembolic event.
  6. Has uncontrolled or significant cardiovascular (CV) disease.
  7. Has corneal disease.
  8. All of the following indicators of interstitial lung disease (ILD)/pneumonitis are excluded:

    1. Any history of ILD/pneumonitis irrespective of use, except for a history of radiation pneumonitis that did not require steroids.
    2. Current diagnosis of ILD.
    3. Clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out. Radiographic findings may include presence of lung parenchymal fibrosis, combined fibrosis and emphysema (CPFE), and/or interstitial lung abnormalities such as reticular opacities, traction bronchiectasis, honeycombing, or extensive ground glass opacities. Screening computed tomography (CT) scans must be submitted for independent central radiology review and results before randomization.
  9. Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses, including, but not limited to, any underlying pulmonary disorder and potential pulmonary involvement caused by any , connective tissue, or inflammatory disorders, prior pneumonectomy, or requirement for supplemental oxygen.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
540 participants (estimated)

Study arms

  • Experimental
    Ifinatamab deruxtecan (I-DXd)

    Participants will be randomized to receive 12 milligrams per kilogram (mg/kg) I-DXd, intravenously (IV), as monotherapy on Day 1 of each 21-day cycle, once every 3 weeks (Q3W), until clinical or radiologic evidence of progression of disease determined by the investigator, unacceptable toxicity, withdrawal of informed consent, death, loss to follow-up, or other treatment discontinuation criteria are met as specified in the protocol.

    Drug: Ifinatamab deruxtecan

  • Active comparator
    Treatment of Physician's Choice (TPC)

    Participants will be randomized to receive topotecan or lurbinectedin, or amrubicin, as per investigator's choice and per locally approved label (indicated dose and frequency), until a treatment discontinuation criteria are met as specified in the protocol.

    Drug: Topotecan · Drug: Amrubicin · Drug: Lurbinectedin

Interventions

  • 12 mg/kg intravenous dose on Day 1 of each 21-day cycle

    Also known as: I-DXd

  • Topotecan will be administered per local standard-of-care (SoC)

  • Amrubicin will be administered per local SoC

  • Lurbinectedin will be administered per local SoC

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is defined as the time interval from the date of randomization to the date of death due to any cause.

    Time frame: From the date of randomization to the date of death due to any cause, up to approximately 3.7 years

Secondary outcomes

  1. Objective Response (OR) Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1)

    Objective response as assessed by BICR is defined as the best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) per BICR according to RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 3.7 years

  2. Number of Participants With OR Assessed by Investigator Per RECIST v1.1

    Objective response as assessed by the investigator is defined as a BOR of confirmed CR or confirmed PR by the investigator according to RECIST v1.1. CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 3.7 years

  3. Progression-free Survival (PFS) as Assessed by BICR and Investigator

    PFS is defined as the time interval from randomization to the earlier date of the first documented radiographic disease progression or death due to any cause.

    Time frame: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 3.7 years

  4. Duration of Response (DoR) as Assessed by BICR and Investigator

    DoR is defined as the time from the date of the first documentation of objective tumor response (CR or PR) that is subsequently confirmed to the date of the first documentation of objective tumor progressive or death to any cause, whichever occurs first. The DoR will be calculated for responding participants (PR or CR) only.

    Time frame: From the date of first documentation of BOR (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first, up to approximately 3.7 years

  5. Disease Control as Assessed by BICR and Investigator

    Disease control is defined as a BOR of confirmed CR, confirmed PR, or stable disease (SD). CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study for target lesions and unequivocal progression of existing non-target lesions for non-target lesions.

    Time frame: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 3.7 years

  6. Time to Response (TTR) as Assessed by BICR and Investigator

    TTR is defined as the time from the date of randomization to the first documentation of objective tumor response (CR or PR) that is subsequently confirmed by BICR and investigator assessment. Time to response (TTR) will be calculated for confirmed responders only.

    Time frame: From the start date of study drug to the date of the first documentation of response (CR or PR) that is subsequently confirmed, up to approximately 3.7 years

  7. Change from Baseline in The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30

    EORTC QLQ-C30 is a 30-item questionnaire that assesses global health status (GHS)/quality of life (QoL), subject functioning, and general cancer symptoms. All scores for the EORTC QLQ-C30 instrument are linearly transformed to a 0 to 100 metric, where a higher score on GHS/QoL and functioning scales indicates a better outcome and a higher score for the symptom scales indicates worse outcomes.

    Time frame: Baseline up to 3.7 years

  8. Change from Baseline in The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 29 (EORTC QLQ-LC29)

    The LC29 is a self-reported 29-item questionnaire that measures SCLC-related symptoms and the side effects of treatments and has a recall period of one week. All scores range from 0 to 100, with a higher score indicating a worse outcome.

    Time frame: Baseline up to 3.7 years

  9. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs are assessed based on NCI CTCAE v5.0.

    Time frame: Up to 3.7 years

  10. Percentage of Participants Who are Anti-Drug Antibody (ADA)-Positive at Any Time (Baseline and Post-baseline) and Who Have a Treatment-emergent Anti-Drug Antibody

    The ADA prevalence, which is the percentage of participants who are ADA positive at any time point (baseline or post-baseline), as well as the ADA incidence, which is the proportion of participants having treatment-emergent ADA during the study period, will only be reported in participants receiving I-DXd.

    Time frame: Baseline up to 3.7 years

  11. Pharmacokinetic Parameter Maximum Concentration (Cmax) for I-DXd, Total Anti-B7-H3 Antibody, and MAAA-1181a

    Cmax will be assessed using non-compartmental methods in participants randomized to the I-DXd group.

    Time frame: Cycle 1 before infusion (BI), end of infusion EOI), and 3, 6, 24, 72, 168, 336 and 504 hours (hrs) post dose; Cycle 2 BI and EOI; Cycle 3 BI, EOI and 6 hrs post dose; Cycles 4, 5, and every 2 cycles thereafter up to 3.7 years BI (each cycle is 21 days)

  12. Pharmacokinetic Parameter Time to Maximum Concentration (Tmax) for I-DXd, Total Anti-B7-H3 Antibody, and MAAA-1181a

    Tmax will be assessed using non-compartmental methods in participants randomized to the I-DXd group.

    Time frame: Cycle 1 before infusion (BI), end of infusion EOI), and 3, 6, 24, 72, 168, 336 and 504 hours (hrs) post dose; Cycle 2 BI and EOI; Cycle 3 BI, EOI and 6 hrs post dose; Cycles 4, 5 and every 2 cycles thereafter up to 3.7 years BI (each cycle is 21 days)

  13. Pharmacokinetic Parameter Area Under the Plasma Concentration-Time Curve Up to the Last Quantifiable Time Point (AUClast) for I-DXd, Total Anti-B7-H3 Antibody, and MAAA-1181a

    AUClast will be assessed using non-compartmental methods in participants randomized to the I-DXd group.

    Time frame: Cycle 1 before infusion (BI), end of infusion EOI), and 3, 6, 24, 72, 168, 336 and 504 hours (hrs) post dose; Cycle 2 BI and EOI; Cycle 3 BI, EOI and 6 hrs post dose; Cycles 4, 5, and every 2 cycles thereafter up to 3.7 years BI (each cycle is 21 days)

  14. Pharmacokinetic Parameter Area Under the Plasma Concentration-Time Curve dosing interval (AUCtau) for I-DXd, Total Anti-B7-H3 Antibody, and MAAA-1181a

    AUCtau will be assessed using non-compartmental methods in participants randomized to the I-DXd group.

    Time frame: Cycle 1 before infusion (BI), end of infusion EOI), and 3, 6, 24, 72, 168, 336 and 504 hours (hrs) post dose; Cycle 2 BI and EOI; Cycle 3 BI, EOI and 6 hrs post dose; Cycles 4, 5, and every 2 cycles thereafter up to 3.7 years BI (each cycle is 21 days)

07

Study locations

189 of 229 sites recruiting
  • Highlands Oncology Group
    Springdale, Arkansas 72762, United States
    Recruiting
    • Principal Investigator · Contact
  • Clinical Research Providence Medical Foundation
    Fullerton, California 92835, United States
    Recruiting
    • Principal Investigator · Contact
  • UCLA Hematology-Oncology
    Los Angeles, California 90095, United States
    Recruiting
    • Principal Investigator · Contact
  • UCSF Mission Bay Mission Hall
    San Francisco, California 94115, United States
    Recruiting
    • Principal Investigator · Contact
  • University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
    Recruiting
    • Principal Investigator · Contact
  • AdventHealth Orlando, Cancer Institute
    Orlando, Florida 32804, United States
    Recruiting
    • Principal Investigator · Contact
  • H. Lee Moffitt Cancer Center and Research Institute, Inc
    Tampa, Florida 33612, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • Rush MD Anderson Cancer Center
    Chicago, Illinois 60612, United States
    Recruiting
    • Principal Investigator · Contact
  • Baptist Health Lexington
    Lexington, Kentucky 40503, United States
    Recruiting
    • Principal Investigator · Contact
  • University of Maryland Greenebaum Comprehensive Cancer Center
    Baltimore, Maryland 21201, United States
    Recruiting
    • Principal Investigator · Contact
  • John Hopkins School of Medicine
    Baltimore, Maryland 21287, United States
    Recruiting
    • Principal Investigator · Contact
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02216, United States
    Recruiting
    • Principal Investigator · Contact
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • Mercy Clinic Oncology and Hematology Sindelar Cancer Center
    St Louis, Missouri 63128, United States
    Recruiting
    • Principal Investigator · Contact
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198-6811, United States
    Recruiting
    • Principal Investigator · Contact
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03766, United States
    Recruiting
    • Principal Investigator · Contact
  • Astera Cancer Care
    East Brunswick, New Jersey 08816, United States
    Recruiting
    • Principal Investigator · Contact
  • Hackensack Meridian Health Jsumc
    Neptune City, New Jersey 07753, United States
    Recruiting
    • Principal Investigator · Contact
  • Clinical Research Alliance, Inc
    Lake Success, New York 11042, United States
    Recruiting
    • Principal Investigator · Contact
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health Long Island
    New York, New York 10016, United States
    Recruiting
    • Principal Investigator · Contact
  • New York University Cancer Center - Laura and Isaac
    New York, New York 10016, United States
    Recruiting
  • Montefiore Medical Center Prime
    The Bronx, New York 10461, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • Cleveland Clinic Mercy Hospital
    Canton, Ohio 44708, United States
    Recruiting
    • Principal Investigator · Contact
  • Oncology/Hematology Care Clinical Trials, Llc
    Cincinnati, Ohio 45236, United States
    Recruiting
    • Principal Investigator · Contact
  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • THE WEST CLINIC, PLLC dba West Cancer Center
    Germantown, Tennessee 38138, United States
    Recruiting
    • Principal Investigator · Contact
  • Houston Methodist Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Principal Investigator · Contact
  • University of Texas Md Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Principal Investigator · Contact
  • Texas Oncology, P.A. - Tyler
    Tyler, Texas 75702, United States
    Recruiting
    • Principal Investigator · Contact
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • Ballarat Base Hospital
    Ballarat, 3350, Australia
    Recruiting
    • Principal Investigator · Contact
  • Flinders Medical Centre (Fmc)
    Bedford Park, 5042, Australia
    Recruiting
    • Principal Investigator · Contact
  • Chris O Brien Lifehouse
    Camperdown, 2050, Australia
    Recruiting
    • Principal Investigator · Contact
  • Sunshine Hospital
    St Albans, 3021, Australia
    Recruiting
    • Principal Investigator · Contact
  • St John of God Subiaco Hospital
    Subiaco, 6008, Australia
    Recruiting
  • Townsville Cancer Centre
    Townsville, 4814, Australia
    Recruiting
    • Principal Investigator · Contact
  • Princess Alexandra Hospital
    Woolloongabba, 4102, Australia
    Recruiting
    • Principal Investigator · Contact
  • Landeskrankenhaus Feldkirch
    Feldkirch, 6800, Austria
    Recruiting
    • Principal Investigator · Contact
  • Landesklinikum Krems
    Krems, 3500, Austria
    Recruiting
    • Principal Investigator · Contact
  • Kepler University Hospital
    Linz, 4020, Austria
    Recruiting
    • Principal Investigator · Contact
  • Wiener Gesundheitsverband Klinik Penzing
    Vienna, 1140, Austria
    Recruiting
    • Principal Investigator · Contact
  • Klinik Floridsdorf
    Vienna, 1210, Austria
    Not yet recruiting
    • Principal Investigator · Contact
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
    Not yet recruiting
    • Principal Investigator · Contact
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
    Recruiting
    • Principal Investigator · Contact
  • Jessa Ziekenhuis Hospital
    Hasselt, 3500, Belgium
    Recruiting
    • Principal Investigator · Contact
  • Centre Hospitalier Universitaire de Liege
    Liège, 4000, Belgium
    Recruiting
    • Principal Investigator · Contact
  • AZ DELTA
    Roeselare, 8800, Belgium
    Not yet recruiting
    • Principal Investigator · Contact
  • Chu Ucl Namur
    Yvoir, 5530, Belgium
    Recruiting
    • Principal Investigator · Contact
  • Departmento de Pesquisa Clinica- Hospital de Amor de Barretos
    Barretos, 14784-400, Brazil
    Recruiting
    • Principal Investigator · Contact
  • Cepon - Centro de Pesquisas Oncolăgicas de Santa Catarina
    Florianópolis, 88034-000, Brazil
    Recruiting
    • Principal Investigator · Contact
  • Clínica de Neoplasias Litoral
    Itajaí, 88301-220, Brazil
    Recruiting
    • Principal Investigator · Contact
  • Hospital São Lucas Da Pucrs
    Porto Alegre, 90610-000, Brazil
    Recruiting
    • Principal Investigator · Contact
  • Cepho Centro de Estudos E Pesquisas de Hematologia E Oncologia
    Santo André, 09060-650, Brazil
    Recruiting
    • Principal Investigator · Contact
  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
    São José do Rio Preto, 15090-000, Brazil
    Recruiting
    • Principal Investigator · Contact
  • ICESP Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira
    São Paulo, 01246-000, Brazil
    Recruiting
    • Principal Investigator · Contact
  • Hospital Sirio-Libanes
    São Paulo, 01308-050, Brazil
    Not yet recruiting
    • Principal Investigator · Contact
  • Hospital Beneficăncia Portuguesa de Săo Paulo
    São Paulo, 01321-001, Brazil
    Recruiting
    • Principal Investigator · Contact
  • Hospital Alemão Oswaldo Cruz
    São Paulo, 01327-001, Brazil
    Recruiting
    • Principal Investigator · Contact
  • A. C. Camargo Cancer Center
    São Paulo, 01509-900, Brazil
    Not yet recruiting
    • Principal Investigator · Contact
  • William Osler Health System - Brampton Civic Hospital
    Brampton, L6R 3J7, Canada
    Recruiting
  • Cross Cancer Institute
    Edmonton, T6G 1Z2, Canada
    Recruiting
    • Principal Investigator · Contact
  • Institut Universitaire de Cardiologie et de Pneumologie de Quebec
    Québec, G1V 4G5, Canada
    Recruiting
    • Principal Investigator · Contact
  • Princess Margaret Cancer Center
    Toronto, M5G 2M9, Canada
    Recruiting
    • Principal Investigator · Contact
  • Cancercare Manitoba
    Winnipeg, R3E0V9, Canada
    Recruiting
    • Principal Investigator · Contact
  • China-Japan Friendship Hospital
    Beijing, 100029, China
    Recruiting
  • Beijing Cancer Hospital
    Beijing, 100142, China
    Recruiting
    • Principal Investigator · Contact
  • Beijing Chest Hospital,Capital Medical University
    Beijing, 101149, China
    Recruiting
    • Principal Investigator · Contact
  • Jilin Province Tumor Hospital
    Changchun, 130012, China
    Recruiting
    • Principal Investigator · Contact
  • Hunan Cancer Hospital
    Changsha, 410013, China
    Recruiting
    • Principal Investigator · Contact
  • Sichuan Cancer Hospital
    Chengdu, 610041, China
    Recruiting
    • Principal Investigator · Contact
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
    Recruiting
    • Principal Investigator · Contact
  • Chongqing University Cancer Hospital
    Chongqing, 400030, China
    Recruiting
    • Principal Investigator · Contact
  • Harbin Medical University Cancer Hospital
    Haerbin, 150081, China
    Not yet recruiting
    • Principal Investigator · Contact
  • The First Affiliated Hospital, College of Medicine, Zhejiang University
    Hangzhou, 310003, China
    Recruiting
    • Principal Investigator · Contact
  • Zhejiang Cancer Hospital
    Hangzhou, 310022, China
    Not yet recruiting
    • Principal Investigator · Contact
  • The Second Affiliated Hospital of Nanchang University
    Jiangxi, 330030, China
    Recruiting
    • Principal Investigator · Contact
  • Shandong Cancer Hospital
    Jinan, 250117, China
    Recruiting
    • Principal Investigator · Contact
  • Linyi Cancer Hospital
    Linyi, 276001, China
    Recruiting
    • Principal Investigator · Contact
  • The Second Peoples Hospital of Neijiang
    Neijiang, 641000, China
    Recruiting
    • Principal Investigator · Contact
  • Yantai Yuhuangding Hospital
    Shandong, 264099, China
    Recruiting
  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
    Not yet recruiting
    • Principal Investigator · Contact
  • Liaoning Cancer Hospital & Institute
    Shenyang, 110042, China
    Recruiting
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, 300060, China
    Recruiting
    • Principal Investigator · Contact
  • The Affiliated Cancer Hospital of Xinjiang Medical University
    Ürümqi, 830000, China
    Recruiting
    • Principal Investigator · Contact
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, 430022, China
    Recruiting
    • Principal Investigator · Contact
  • Huazhong University of Science and Technology - Tongji Medical College - Tongji Hospital Tjh
    Wuhan, 430030, China
    Recruiting
    • Principal Investigator · Contact
  • Hubei Cancer Hospital
    Wuhan, 430079, China
    Not yet recruiting
    • Principal Investigator · Contact
  • The First Affiliated Hospital of Xiân Jiaotong University
    Xi'an, 710061, China
    Recruiting
  • Xiangyang Central Hospital
    Xiangyang, 441021, China
    Not yet recruiting
    • Principal Investigator · Contact
  • Henan Cancer Hospital
    Zhengzhou, 450008, China
    Recruiting
    • Principal Investigator · Contact
  • Krajska Nemocnice Liberec A.S.
    Liberec, 460 63, Czechia
    Recruiting
    • Principal Investigator · Contact
  • Fakultni Nemocnice Olomouc
    Olomouc, 77900, Czechia
    Recruiting
    • Principal Investigator · Contact
  • Fakultni Thomayerova Nemocnice
    Prague, 140 59, Czechia
    Recruiting
    • Principal Investigator · Contact
  • Institut Sainte Catherine
    Avignon, 84000, France
    Recruiting
    • Principal Investigator · Contact
  • Chu Bordeaux
    Bordeaux, 33075, France
    Not yet recruiting
    • Principal Investigator · Contact
  • Centre Hospitalier Intercommunal de Crăteil
    Créteil, 94010, France
    Recruiting
    • Principal Investigator · Contact
  • Institut Cœur Poumon CHU de Lille
    Lille, 69037, France
    Recruiting
  • Chu Limoges - Hopital Du Cluzeau
    Limoges, 87042, France
    Recruiting
    • Principal Investigator · Contact
  • Centre Léon Bérard
    Lyon, 69008, France
    Not yet recruiting
    • Principal Investigator · Contact
  • Assistance Publique-Hăpitaux de Marseille
    Marseille, 13005, France
    Recruiting
    • Principal Investigator · Contact

Showing the first 100 of 229 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Owonikoko TK, Byers L, Cheng Y, Hayashi H, Paz-Ares L, Perol M, Hu H, Qian M, Garcia CR, Godard J, Tang M, Rudin CM. IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer. Future Oncol. 2025 Oct;21(25):3275-3282. doi: 10.1080/14796694.2025.2565995. Epub 2025 Oct 7. PubMed 41055143 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Jan 2028, 44 months after the start.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 44 months is above that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2024
First posted
Jan 12, 2024
StartActual
May 21, 2024
Primary completionEst.
Jan 30, 2028
CompletionEst.
Dec 1, 2029
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06203210
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Jan 12, 2024
Start date
May 21, 2024
Primary completion
Jan 30, 2028 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Aug 6, 2026

Study contacts

Daiichi Sankyo Contact for Clinical Trial Information
Contact
CTRinfo@dsi.com
9089926400
Global Clinical Director
study director · Daiichi Sankyo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ifinatamab deruxtecan

Start the discussion